Nuveen Asset Management LLC decreased its position in Amedisys Inc (NASDAQ:AMED) by 18.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,718 shares of the health services provider’s stock after selling 2,481 shares during the quarter. Nuveen Asset Management LLC’s holdings in Amedisys were worth $1,255,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Navellier & Associates Inc boosted its position in Amedisys by 148.7% during the fourth quarter. Navellier & Associates Inc now owns 17,558 shares of the health services provider’s stock valued at $2,056,000 after purchasing an additional 10,499 shares during the last quarter. Advisors Asset Management Inc. lifted its position in shares of Amedisys by 67.2% in the third quarter. Advisors Asset Management Inc. now owns 28,567 shares of the health services provider’s stock worth $3,570,000 after buying an additional 11,486 shares during the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in shares of Amedisys in the third quarter worth about $2,174,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Amedisys by 15.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,900 shares of the health services provider’s stock worth $223,000 after buying an additional 251 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Amedisys in the third quarter worth about $3,411,000. 91.86% of the stock is currently owned by institutional investors and hedge funds.
Shares of AMED traded up $1.58 on Friday, hitting $117.22. The company’s stock had a trading volume of 507,085 shares, compared to its average volume of 324,167. The company has a market capitalization of $3.75 billion, a P/E ratio of 32.29, a PEG ratio of 1.47 and a beta of 1.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.01 and a quick ratio of 1.01. Amedisys Inc has a fifty-two week low of $63.00 and a fifty-two week high of $140.91.
In other news, Director Jeffrey A. Rideout sold 1,411 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $121.58, for a total value of $171,549.38. Following the transaction, the director now owns 4,557 shares of the company’s stock, valued at approximately $554,040.06. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider David B. Pearce sold 4,370 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $120.01, for a total transaction of $524,443.70. Following the completion of the sale, the insider now owns 13,129 shares of the company’s stock, valued at approximately $1,575,611.29. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,281 shares of company stock worth $993,393. Company insiders own 2.60% of the company’s stock.
Several equities analysts recently weighed in on the company. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating in a research report on Monday, January 21st. ValuEngine raised Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Benchmark lowered Amedisys from a “buy” rating to a “hold” rating and set a $136.64 price target on the stock. in a research note on Tuesday, February 5th. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 14th. Finally, SunTrust Banks boosted their price target on Amedisys to $145.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $124.72.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Article: Put Option Volume
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.